Chimeric Therapeutics (ASX:CHM) doses first patient in cell therapy trial

August 27, 2024 07:44 PM PDT | By Sonal Goyal

Google News:

Chimeric Therapeutics (ASX:CHM) doses first patient in cell therapy trial — Image source: Shutterstock

Recent News

DoubleVerify Sees Update in Digital Ad Tech Sector Russell 1000

Pagaya Technologies PGY Gains Support Nasdaq Index Stocks Watch

Oceaneering International OII Sees Institutional Growth on NYSE Compos...

GAMMA Expands Stake in Valvoline Inc Amid Market Movements S&P 500

Highlights

The first patient in the Phase 1/2 clinical trial of CHM CDH17 has been dosed at the Sarah Cannon Research Institute in Tennessee.

Patient recruitment for this first-in-human clinical trial is currently underway at cancer centers across the United States.

Phase 1 of the trial aims to enrol 15 patients.

Chimeric Therapeutics Limited (ASX:CHM) has reached a significant milestone in its Phase 1/2 clinical trial of CDH17-directed CAR-T cell therapy with the dosing of the first patient at Sarah Cannon Research Institute in Tennessee, the United States.

CHM CDH17 is a third generation CAR T cell therapy targeting CDH17, a cancer marker associated with poor prognosis and metastasis in gastrointestinal tumours. Recruitment for this two-stage, first-in-human clinical trial is progressing at cancer centres across the United States.

Data source: Company update

Phase 1 of this trial is anticipated to enrol 15 patients and will include dose selection and expansion with indication-specific Phase 2 cohorts.

Data source: Company update

CHM shares trade higher

CHM shares traded at AU$0.017 apiece, up more than 6%, at the time of writing on 28 August 2024.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.